Abstract
This table presents a comparison of the binding epitopes of botensilimab, ipilimumab, and tremelimumab on human CTLA-4. It highlights the specific amino acid residues on CTLA-4 that are involved in the binding interface for each antibody. This comparison provides insight into binding characteristics of botensilimab relative to established anti-CTLA-4 therapies.